James A Wimsatt Iii, DDS Dentist - Oral and Maxillofacial Surgery Medicare: May Accept Medicare Assignments Practice Location: 5955 Zeamer Ave, Elmendorf Afb, AK 99506 Phone: 907-580-5202 Fax: 907-580-5022 |
Peter M Pedalino, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 5955 Zeamer Ave, Elmendorf Afb, AK 99506 Phone: 907-580-5010 |
Dr. Richard Michael Luff, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 5955 Zeamer Ave, Elmendorf Afb, AK 99506 Phone: 907-580-5052 |
Dr. Ricky David Cook, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 3rd Medical Group, 5955 Zeamer Drive, Elmendorf Afb, AK 99506 Phone: 907-580-5010 |
Dr. Eric Brown, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 5955 Zeamer Ave, 3rd Mdg/sgd, Elmendorf Afb, AK 99506 Phone: 907-580-5106 |
David Lawton Robinson, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 5955 Zeamer Ave, 3rd Dental Squadron/sgd, Elmendorf Afb, AK 99506 Phone: 907-580-5010 |
Brian Ng, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 5955 Zeamer Ave Bldg 5955, Elmendorf Afb, AK 99506 Phone: 907-580-5010 |
Dr. Richard Alan Vanderweele, D.M.D. Dentist - Endodontics Medicare: Not Enrolled in Medicare Practice Location: 5955 Zeamer Ave, 3rd Ds/sgd, Elmendorf Afb, AK 99506 Phone: 907-580-2973 Fax: 907-580-5022 |
News Archive
Inhibiting infants' tongue movements impedes their ability to distinguish between speech sounds, researchers with the University of British Columbia have found. The study is the first to discover a direct link between infants' oral-motor movements and auditory speech perception.
In the largest study of its kind to date, researchers have used DNA sequencing to uncover dozens of genes that heighten the risk for autism. Joseph Buxbaum, Ph.D., Icahn School of Medicine at Mount Sinai, New York City, Mark Daly, Ph.D., Broad Institute of Harvard and MIT, and their colleagues examined more than 14,000 DNA samples from affected children, parents and unrelated people.
Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.
Studies have shown that utilizing a PARP inhibitor in the management of patients with metastatic pancreatic cancer who harbor BRCA 1/2 mutations is clinically beneficial.
Antimuscarinics "could and should" be used in the pharmacological treatment of men with lower urinary tract symptoms caused by benign prostatic hyperplasia or bladder outlet obstruction, say the authors of a meta-analysis published in Urology.
› Verified 2 days ago